Proton pump inhibitor leaflets: Is there information on deprescribing?

Proton pump inhibitor leaflets: Is there information on deprescribing?

Abstract This study aims to analyze the existence of information about deprescription in the leaflets of proton pump inhibitor (PPI) medications. The leaflets available on the Brazilian Health Regulatory Agency (ANVISA) and Food and Drug Administration (FDA) websites for the following medications we...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcus Vinícius Lopes Campos, Farah Maria Drumond Chequer, Luanna Gabriella Resende da Silva, André Oliveira Baldoni
Format: Article
Language:English
Published: Universidade de São Paulo 2025-01-01
Series:Brazilian Journal of Pharmaceutical Sciences
Subjects:
Leaflet
Deprescription
Rational Use of Medicines
Proton Pump Inhibitors
Brazilian Health Regulatory Agency (ANVISA)
Food and Drug Administration (FDA)
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100805&lng=en&tlng=en
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This study aims to analyze the existence of information about deprescription in the leaflets of proton pump inhibitor (PPI) medications. The leaflets available on the Brazilian Health Regulatory Agency (ANVISA) and Food and Drug Administration (FDA) websites for the following medications were analyzed: omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. The variables collected in each leaflet were the existence: a) about deprescribing; b) of guidance on the deprescription process; c) maximum recommended time for use; and d) risk of prolonged use. This information was analyzed in accordance with the PPI deprescription guideline, from Canada. Regarding the medication leaflets, 83.33 % from ANVISA and 100 % from the FDA did not present explicit and systematic guidance on deprescribing. Regarding the maximum time of use, 100 % of the leaflets from both agencies contained this information. Regarding the risks of prolonged use of the medication, 33.33 % of the ANVISA leaflets and 33.3 % of the FDA leaflets did not report the increased risks described in the guideline. The results highlight a large gap in information about deprescribing in PPI leaflets; this highlighting is necessary to contribute to the promotion of the rational use of medicines.
ISSN:2175-9790

Similar Items